Document Type
Journal Article
Publication Title
Frontiers in Immunology
Publisher
Frontiers Media S.A.
School
School of Medical and Health Sciences
RAS ID
37014
Funders
Edith Cowan University - Open Access Support Scheme 2021
National Health and Medical Research Council
National Natural Science Foundation of China
China-Australia International Collaborative Grant
European Commission Horizon 2020 Framework Program
Grant Number
NHMRC Number : APP1112767
Abstract
Coronavirus disease 2019 (COVID-19) remains a major health challenge globally. Previous studies have suggested that changes in the glycosylation of IgG are closely associated with the severity of COVID-19. This study aimed to compare the profiles of IgG N-glycome between COVID-19 patients and healthy controls. A case-control study was conducted, in which 104 COVID-19 patients and 104 age- and sex-matched healthy individuals were recruited. Serum IgG N-glycome composition was analyzed by hydrophilic interaction liquid chromatography with the ultra-high-performance liquid chromatography (HILIC-UPLC) approach. COVID-19 patients have a decreased level of IgG fucosylation, which upregulates antibody-dependent cell cytotoxicity (ADCC) in acute immune responses. In severe cases, a low level of IgG sialylation contributes to the ADCC-regulated enhancement of inflammatory cytokines. The decreases in sialylation and galactosylation play a role in COVID-19 pathogenesis via the activation of the lectin-initiated alternative complement pathway. IgG N-glycosylation underlines the complex clinical phenotypes of SARS-CoV-2 infection.
DOI
10.3389/fimmu.2021.748566
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Comments
Hou, H., Yang, H., Liu, P., Huang, C., Wang, M., Li, Y., . . . Wang, W. (2021). Profile of immunoglobulin G N-glycome in COVID-19 patients: A case-control study. Frontiers in Immunology, 12, article 748566. https://doi.org/10.3389/fimmu.2021.748566